Extent of Removal for Mediastinal Nodal Stations for Patients with Clinical Stage I Non-Small Cell Lung Cancer: Effect on Outcome

Abstract

Background Lobectomy and mediastinal lymph node dissection comprise the standard surgical treatment for non-small cell lung cancer (NSCLC). Although complete mediastinal lymph node dissection has been recommended as part of the procedure for achieving complete resection, the benefits for early lung cancer are unclear. The purpose of this study was to determine the effects of different degrees of mediastinal lymph node dissection on the clinical outcomes of patients with clinical stage I NSCLC.

Materials and Methods The records of patients with clinical stage I NSCLC treated between January 2000 and September 2010 were reviewed retrospectively. This study consisted of 211 patients who underwent lobectomy plus mediastinal lymph node dissection and sampling. Patients were divided into a group who underwent lymphadenectomy (LA) including complete mediastinal node dissection or lobe-specific lymph node dissection and a group who underwent selective lymph node sampling (LS). Clinical outcomes, including survival, and prognostic factors were determined.

Results The mean (±) number of extracted lymph nodes for the LS and LA patients was 7.50 ± 5.44 and 14.09 ± 7.57, respectively (p < 0.001). Male and diabetes mellitus patients were more associated with LS. Survival of the LA patients was significantly longer (p = 0.029). By multivariate analysis, extent of mediastinal nodal sampling (p = 0.029) and positive for mediastinal nodal (N2-positive) disease (p = 0.046) were significant predictors for survival.

Conclusions The extent of dissection of mediastinal lymph nodes affected the clinical outcomes of our study patients with clinical stage I NSCLC. At least evaluation of lobe-specific lymph node dissection is required.

Keywords

chest - lung cancer treatment - outcomes

• References

• 1 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5) 277-300
• 2 Cahan WG. Radical lobectomy. J Thorac Cardiovasc Surg 1960; 39: 555-572
• 3 Strand TE, Rostad H, Møller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 2006; 61 (8) 710-715
• 4 Goya T, Asamura H, Yoshimura H , et al; Japanese Joint Committee of Lung Cancer Registry. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50 (2) 227-234
• 5 Rami-Porta R, Wittekind C, Goldstraw P. International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 2005; 49 (1) 25-33
• 6 Keller SM, Adak S, Wagner H, Johnson DH. Eastern Cooperative Oncology Group. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg 2000; 70 (2) 358-365 , discussion 365–366
• 7 Kim S, Kim HK, Kang DY, Jeong JM, Choi YH. Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, 99mTc-MSA) in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2010; 37 (6) 1450-1456
• 8 Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done?. Eur J Cardiothorac Surg 1999; 16 (Suppl. 01) S17-S24
• 9 Martini N. Mediastinal lymph node dissection for lung cancer. The memorial experience. Chest Surg Clin N Am 1995; 5 (2) 189-203
• 10 Izbicki JR, Passlick B, Pantel K , et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 1998; 227 (1) 138-144
• 11 Verhagen AF, Schoenmakers MC, Barendregt W , et al. Completeness of lung cancer surgery: is mediastinal dissection common practice?. Eur J Cardiothorac Surg 2012; 41 (4) 834-838
• 12 Melfi FMA, Davini F, Boni G, Mussi A. Sentinel lymph node in lung cancer surgery. Thorac Surg Clin 2012; 22 (2) 205-214
• 13 Shi CL, Zhang XY, Han BH, He WZ, Shen J, Chu TQ. A clinicopathological study of resected non-small cell lung cancers 2 cm or less in diameter: a prognostic assessment. Med Oncol 2011; 28 (4) 1441-1446
• 14 Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg 2005; 80 (1) 268-274 , discussion 274–275
• 15 Darling GE, Allen MS, Decker PA , et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011; 141 (3) 662-670
• 16 Hughes MJ, Chowdhry MF, Woolley SM, Walker WS. In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior?. Interact Cardiovasc Thorac Surg 2011; 13 (3) 311-315
• 17 Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003; 21 (6) 1029-1034
• 18 Wu YC, Lin CF, Hsu WH, Huang BS, Huang MH, Wang LS. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg 2003; 24 (6) 994-1001
• 19 Ou SH, Zell JA. Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer. J Thorac Oncol 2008; 3 (8) 880-886
• 20 Muraoka M, Akamine S, Oka T , et al. Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32 (2) 356-361
• 21 Cerfolio RJ, Bryant AS, Minnich DJ. Complete thoracic mediastinal lymphadenectomy leads to a higher rate of pathologically proven N2 disease in patients with non-small cell lung cancer. Ann Thorac Surg 2012; 94 (3) 902-906
• 22 Doddoli C, Aragon A, Barlesi F , et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?. Eur J Cardiothorac Surg 2005; 27 (4) 680-685